• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda .

作者信息

Immisch Lena, Papafotiou George, Popp Oliver, Mertins Philipp, Blankenstein Thomas, Willimsky Gerald

机构信息

Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

German Cancer Research Center, Heidelberg, Germany.

出版信息

J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2023-006784.

DOI:10.1136/jitc-2023-006784
PMID:36918223
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10016299/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41e9/10016299/140b793a352d/jitc-2023-006784f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41e9/10016299/140b793a352d/jitc-2023-006784f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41e9/10016299/140b793a352d/jitc-2023-006784f01.jpg

相似文献

1
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda .对Chheda的《关于“H3.3K27M突变并非HLA - A2阳性弥漫性中线胶质瘤患者免疫治疗合适靶点”的通信》的回复
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2023-006784.
2
Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch .关于Immisch所著的《H3.3K27M突变并非HLA - A2 +弥漫性中线胶质瘤患者免疫治疗的合适靶点》的通信
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006617.
3
H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2 patients with diffuse midline glioma.H3.3K27M 突变不是 HLA-A2 型弥漫性中线胶质瘤患者免疫治疗的合适靶点。
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005535.
4
Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.新型和共享的组蛋白 3 变体 H3.3K27M 突变衍生的神经抗原用于胶质细胞瘤 T 细胞治疗。
J Exp Med. 2018 Jan 2;215(1):141-157. doi: 10.1084/jem.20171046. Epub 2017 Dec 4.
5
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.质谱细胞术检测弥漫性中线胶质瘤中 H3.3K27M 特异性疫苗反应。
J Clin Invest. 2020 Dec 1;130(12):6325-6337. doi: 10.1172/JCI140378.
6
Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.组蛋白 H3.3K27M 在小儿神经胶质瘤中动员多种癌/睾丸（CT）抗原。
Mol Cancer Res. 2018 Apr;16(4):623-633. doi: 10.1158/1541-7786.MCR-17-0460. Epub 2018 Feb 16.
7
Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.检测弥漫性中线胶质瘤患儿脑脊液来源肿瘤 DNA 中的组蛋白 H3 突变。
Acta Neuropathol Commun. 2017 Apr 17;5(1):28. doi: 10.1186/s40478-017-0436-6.
8
Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.利用 ddPCR 对小儿弥漫性中线脑胶质瘤进行液体活检的标准化。
Sci Rep. 2021 Mar 3;11(1):5098. doi: 10.1038/s41598-021-84513-1.
9
Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma.局限于HLA-A∗02:01的内源性H3.3K27M衍生肽不足以在弥漫性中线胶质瘤中进行免疫靶向。
Mol Ther Oncolytics. 2023 Aug 15;30:167-180. doi: 10.1016/j.omto.2023.08.005. eCollection 2023 Sep 21.
10
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.组蛋白 H3.3K27M 突变在小儿神经胶质瘤中重塑 H3K27 甲基化和基因表达。
Genes Dev. 2013 May 1;27(9):985-90. doi: 10.1101/gad.217778.113. Epub 2013 Apr 19.

本文引用的文献

1
Unconventional modes of peptide-HLA-I presentation change the rules of TCR engagement.肽-HLA-I呈递的非常规模式改变了TCR结合的规则。
Discov Immunol. 2022 May 4;1(1):kyac001. doi: 10.1093/discim/kyac001. eCollection 2022.
2
H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2 patients with diffuse midline glioma.H3.3K27M 突变不是 HLA-A2 型弥漫性中线胶质瘤患者免疫治疗的合适靶点。
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005535.
3
Reciprocal H3.3 gene editing identifies K27M and G34R mechanisms in pediatric glioma including NOTCH signaling.
同源 H3.3 基因编辑鉴定出包括 NOTCH 信号通路在内的小儿神经胶质瘤中的 K27M 和 G34R 机制。
Commun Biol. 2020 Jul 9;3(1):363. doi: 10.1038/s42003-020-1076-0.
4
Chronic irradiation of human cells reduces histone levels and deregulates gene expression.慢性辐射会降低人类细胞中的组蛋白水平，并使基因表达失调。
Sci Rep. 2020 Feb 10;10(1):2200. doi: 10.1038/s41598-020-59163-4.
5
Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.新型和共享的组蛋白 3 变体 H3.3K27M 突变衍生的神经抗原用于胶质细胞瘤 T 细胞治疗。
J Exp Med. 2018 Jan 2;215(1):141-157. doi: 10.1084/jem.20171046. Epub 2017 Dec 4.
6
K27M-mutant histone-3 as a novel target for glioma immunotherapy.K27M突变型组蛋白-3作为神经胶质瘤免疫治疗的新靶点。
Oncoimmunology. 2017 May 12;6(7):e1328340. doi: 10.1080/2162402X.2017.1328340. eCollection 2017.
7
Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.伴组蛋白H3-K27M突变的弥漫性中线胶质瘤：47例病例系列研究，评估形态学变异谱及相关基因改变
Brain Pathol. 2016 Sep;26(5):569-80. doi: 10.1111/bpa.12336. Epub 2015 Dec 14.
8
Ionizing radiation affects 26s proteasome function and associated molecular responses, even at low doses.即使在低剂量下，电离辐射也会影响26S蛋白酶体功能及相关分子反应。
Radiother Oncol. 2001 May;59(2):203-12. doi: 10.1016/s0167-8140(01)00311-5.